Research
Hormonal
Semaglutide (2.4 mg weekly) produces significant weight loss (approx. 15%) by acting as a GLP-1 receptor agonist that stimulates satiety centers in the hypothalamus.
Semaglutide is a weekly injectable medication that mimics a gut hormone to signal fullness to the brain. Clinical trials show it can lead to roughly 15% body weight loss when combined with lifestyle changes, significantly outperforming lifestyle changes alone. It requires a prescription and ongoing medical supervision.
StrongSupportsHIGH confidence
Semaglutide is an analog of human glucagon-like peptide-1 (GLP-1)... The mechanism of action of semaglutide involves both peripheral and central effects... In the central nervous system, semaglutide primarily acts on GLP-1 receptors located in the hypothalamus... Those treated with semaglutide achieved an average weight reduction of 14.9%...
Why this rating
Based on large, randomized, double-blind, placebo-controlled trials (STEP 1, STEP 3).
Source
TRENDS IN OBESITY TREATMENT: A REVIEW OF THE LITERATURE FROM THE LAST SIX YEARS
Adam Sobiński et al. · International Journal of Innovative Technologies in Social Science · 2025
narrative_review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →